{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:47:32Z","timestamp":1791002852694,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>\n                    Although management of multiple myeloma has changed substantially in the last decade, it is unknown whether the burden of ESRD due to multiple myeloma has changed, or whether survival of patients with multiple myeloma on RRT has improved. Regarding ESRD due to multiple myeloma necessitating RRT in the United States, we evaluated temporal trends between 2001 and 2010 for demography-adjusted incidence ratios, relative to rates in 2001\u20132002, and mortality hazards from RRT initiation, relative to hazards in 2001\u20132002. In this retrospective cohort study, we used the US Renal Data System database (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    =1,069,343), 2001\u20132010, to identify patients with ESRD due to multiple myeloma treated with RRT (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    =12,703). Demography-adjusted incidence ratios of ESRD from multiple myeloma decreased between 2001\u20132002 and 2009\u20132010 in the overall population (demography-adjusted incidence ratio 0.82; 95% confidence interval, 0.79 to 0.86) and in most demographic subgroups examined. Mortality rates were 86.7, 41.4, and 34.4 per 100 person-years in the first 3 years of RRT, respectively, compared with 32.3, 20.6, and 21.3 in matched controls without multiple myeloma. Unadjusted mortality hazards ratios declined monotonically after 2004 to a value of 0.72; 95% confidence interval, 0.67 to 0.77 in 2009\u20132010, and declines between 2001\u20132002 and 2008\u20132009 were observed (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.05) in most demographic subgroups examined. Findings were similar when adjustment was made for demographic characteristics, comorbidity markers, and laboratory test values. These data suggest the incidence of RRT from multiple myeloma in the United States has decreased in the last decade, and clinically meaningful increases in survival have occurred for these patients.\n                  <\/jats:p>","DOI":"10.1681\/asn.2014090876","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T23:08:06Z","timestamp":1446160086000},"page":"1487-1494","source":"Crossref","is-referenced-by-count":35,"title":["ESRD due to Multiple Myeloma in the United States, 2001\u20132010"],"prefix":"10.1681","volume":"27","author":[{"given":"Scott","family":"Reule","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis, Minnesota; and"},{"name":"Minneapolis Medical Research Foundation, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal J.","family":"Sexton","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis, Minnesota; and"},{"name":"Minneapolis Medical Research Foundation, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Solid","sequence":"additional","affiliation":[{"name":"Minneapolis Medical Research Foundation, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Minneapolis Medical Research Foundation, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Foley","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis, Minnesota; and"},{"name":"Minneapolis Medical Research Foundation, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2015,10,29]]},"reference":[{"key":"B1-20230819","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/ndt\/gfp679","article-title":"Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study.","volume":"25","author":"Tsakiris","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"B2-20230819","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma.","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B3-20230819","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"B4-20230819","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"B5-20230819","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"B6-20230819","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma.","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"B7-20230819","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"B8-20230819","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"B9-20230819","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"B10-20230819","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma.","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"B11-20230819","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"B12-20230819","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1681\/ASN.2006020139","article-title":"Multiple myeloma.","volume":"17","author":"Korbet","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B13-20230819","first-page":"207","article-title":"Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival.","volume":"56","author":"Abbott","year":"2001","journal-title":"Clin Nephrol"},{"key":"B14-20230819","first-page":"e29","article-title":"Heart disease and stroke statistics--2015 update: a report from the American Heart Association.","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"B15-20230819","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"B16-20230819","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma.","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"B17-20230819","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"B18-20230819","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"B19-20230819","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma.","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"B20-20230819","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.","volume":"124","author":"Bringhen","year":"2014","journal-title":"Blood"},{"key":"B21-20230819","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/leu.2014.23","article-title":"Improved long-term survival in multiple myeloma up to the age of 80 years.","volume":"28","author":"Kristinsson","year":"2014","journal-title":"Leukemia"},{"key":"B22-20230819","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.12465","article-title":"Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.","volume":"163","author":"Pozzi","year":"2013","journal-title":"Br J Haematol"},{"key":"B23-20230819","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.","volume":"28","author":"Turesson","year":"2010","journal-title":"J Clin Oncol"},{"key":"B24-20230819","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study.","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"B25-20230819","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000358497","article-title":"Impact of age, race and ethnicity on dialysis patient survival and kidney transplantation disparities.","volume":"39","author":"Rhee","year":"2014","journal-title":"Am J Nephrol"},{"key":"B26-20230819","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/jnci\/djp435","article-title":"StatBite: Multiple myeloma and African Americans: higher incidence but fewer autologous stem cell transplants.","volume":"101","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"B27-20230819","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/COC.0b013e3180592a30","article-title":"Chemotherapy and survival for patients with multiple myeloma: findings from a large nationwide and population-based cohort.","volume":"30","author":"Rohatgi","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"B28-20230819","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1038\/bcj.2015.8","article-title":"Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.","volume":"5","author":"Greenberg","year":"2015","journal-title":"Blood Cancer J"},{"key":"B29-20230819","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"B31-20230819","first-page":"1","article-title":"Variations in specialist palliative care referrals: findings from a population-based patient cohort of acute myeloid leukaemia, diffuse large B-cell lymphoma and myeloma.","volume":"0","author":"Howell","year":"2014","journal-title":"BMJ Support Palliat Care"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201605000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:27:15Z","timestamp":1786130835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201605000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,29]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2014090876","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,29]]}}}